Once-Daily pill may protect blood vessels better in black kidney transplant patients
NCT ID NCT03841097
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This study looks at two versions of the drug tacrolimus, which is used to prevent organ rejection after a kidney transplant. One version is taken once a day, the other twice a day. The goal is to see which one does a better job at keeping blood vessels healthy, measured by how stiff they are. The study involves 60 African American kidney transplant recipients and will follow them for up to two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT; COMPLICATIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tacrolimus (extended-release and immediate-release forms)
What this could lead to
If successful, this could show that a once-daily version of tacrolimus is better for heart and blood vessel health than the twice-daily version in African American kidney transplant patients.
What could go wrong
This is a small, single-center study with only 60 participants, so results may not apply to all patients. The study is also observational in nature and does not test a new drug, so any benefits are about choosing between existing options.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.